Overview
- Focus on next-generation ADCs for oncology and other diseases
- Description & analysis of current technological innovations for ADCs
- ADC clinical development in the context of immuno-oncology
Part of the book series: Cancer Drug Discovery and Development (CDD&D)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (14 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases.
The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Editors and Affiliations
About the editor
Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation.
Bibliographic Information
Book Title: Innovations for Next-Generation Antibody-Drug Conjugates
Editors: Marc Damelin
Series Title: Cancer Drug Discovery and Development
DOI: https://doi.org/10.1007/978-3-319-78154-9
Publisher: Humana Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer International Publishing AG, part of Springer Nature 2018
Hardcover ISBN: 978-3-319-78153-2Published: 11 June 2018
Softcover ISBN: 978-3-030-08627-5Published: 08 February 2019
eBook ISBN: 978-3-319-78154-9Published: 29 May 2018
Series ISSN: 2196-9906
Series E-ISSN: 2196-9914
Edition Number: 1
Number of Pages: VIII, 357
Number of Illustrations: 18 b/w illustrations, 52 illustrations in colour
Topics: Cancer Research, Molecular Medicine